Peregrine to Present at Wedbush Securities Life Sciences Management Access Conference on August 15, 2012 at 10:55 AM EDT
(firmenpresse) - TUSTIN, CA -- (Marketwire) -- 08/08/12 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer and infectious diseases, today announced that Steven King, president and CEO, will present at the Wedbush Securities Life Sciences Management Access Conference at Le Parker Meridien Hotel in New York, NY on August 15, 2012 at 10:55 AM Eastern Daylight Time.
Peregrine's presentation will be webcast live and available for replay until August 29, 2012 at:
For more information about this conference, please visit:
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and infectious diseases with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at .
Contact:
Christopher Keenan or Jay Carlson
Peregrine Pharmaceuticals
(800) 987-8256
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 08.08.2012 - 14:05 Uhr
Sprache: Deutsch
News-ID 1140727
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
TUSTIN, CA
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 136 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Peregrine to Present at Wedbush Securities Life Sciences Management Access Conference on August 15, 2012 at 10:55 AM EDT
"
steht unter der journalistisch-redaktionellen Verantwortung von
Peregrine Pharmaceuticals (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
